- ►wanfang.gov.tw [DOC] RE Amori, J Lau, AG Pittas - Jama, 2007 - Am Med Assoc You are seeing this message because your Web browser does not support basic Web
standards. Find out more about why this message is appearing and what you can do
to make your experience on this site better. ... Add to CiteULike Add to ... Cited by 240 - Related articles - BL Direct - All 8 versions
- ►rh.dk [PDF] LL Baggio, DJ Drucker - Gastroenterology, 2007 - Elsevier This review focuses on the mechanisms regulating the synthesis, secretion,
biological actions, and therapeutic relevance of the incretin peptides
glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like ... Cited by 173 - Related articles - All 25 versions
MA Nauck, G Meininger, D Sheng, L Terranella … - Diabetes, Obesity and Metabolism, 2007 - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 132 - Related articles - All 7 versions
DM Nathan - New England Journal of Medicine, 2007 - content.nejm.org Two modern-day epidemics, HIV–AIDS and type 2 diabetes mellitus, have inspired
impassioned calls for more effective interventions. In the 1980s, the rapid
spread of HIV, with its associated severe, acute illness and high ... Cited by 112 - Related articles - BL Direct - All 7 versions
- ►diabetesjournals.org BJ Goldstein, MN Feinglos, JK Lunceford, J … - Diabetes Care, 2007 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—In a 24-week, randomized, double-blind,
placebo-controlled, parallel-group study, 1,091 patients with type 2 diabetes
and A1C 7.5–11% were randomized to one of six daily treatments: ... Cited by 94 - Related articles - BL Direct - All 9 versions
K Hermansen, M Kipnes, E Luo, D Fanurik, H … - Diabetes Obes Metab, 2007 - januvia.com Thank you for your interest in the enclosed reprint, “Efficacy and Safety of
the Dipeptidyl Peptidase-4 Inhibitor, Sitagliptin, in Patients With Type 2
Diabetes Mellitus Inadequately Controlled on Glimepiride Alone or on ... Cited by 74 - Related articles - View as HTML - All 5 versions
- ►diabetesjournals.org B Ahrén - Diabetes Care, 2007 - Am Diabetes Assoc The enzyme dipeptidyl peptidase-4 (DPP-4) prevents the inactivation of
glucagon-like peptide-1 (GLP-1). Since GLP-1–based therapy is a promising
novel treatment of type 2 diabetes, the strategy to inhibit the enzyme has ... Cited by 51 - Related articles - BL Direct - All 11 versions
A Garber, R Henry, R Ratner, PA Garcia- … - The Lancet, 2009 - Elsevier In a double-blind, double-dummy, active-control, parallel-group study, 746
patients with early type 2 diabetes were randomly assigned to once daily
liraglutide (1·2 mg [n=251] or 1·8 mg [n=247]) or glimepiride 8 mg ... Cited by 54 - Related articles - All 46 versions
GA Herman, PP Stein, NA Thornberry, JA … - Clinical Pharmacology & Therapeutics, 2007 - nature.com Dipeptidyl peptidase-4 (DPP-4) inhibitors represent a new class of oral
antihyperglycemic agents to treat patients with type 2 diabetes. 1 DPP-4
inhibitors improve fasting and postprandial glycemic control without ... Cited by 29 - Related articles - All 4 versions
PS Jellinger, JA Davidson, L Blonde, D … - Endocrine Practice, 2007 - AACE The accompanying Diabetes Road Maps were created to provide direction for
clinicians in achieving the hemo- globin A1c (A1C) glycemic goals established by
the American College of Endocrinology (ACE) and the American Association of ... Cited by 30 - Related articles - All 6 versions
